scientists the tools they need to develop drugs that block nmMLCK. They are particularly interested in a molecular pathway called Src (pronounced "sarc) that is activated by nmMLCK. Src is known to be involved in other diseases, including osteoporosis and certain cancers.We need to fully profile this protein and its interactions with other molecules to identify the best possible way to block it